Corvus Pharmaceu Stock Price, News & Analysis

Corvus Pharmaceuticals (Nasdaq: CRVS) announced positive results from a COVID-19 randomized controlled study involving 40 patients treated with mupadolimab, showing improved primary and secondary endpoints compared to placebo. The Phase 3 trial, though discontinued voluntarily, indicated a potential dose-response effect, particularly at 2mg/kg, with no reported adverse events. The company is also conducting a Phase 1b/2 trial for mupadolimab in oncology, with data expected to be presented at the SITC meeting in November.

Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced participation in two investor conferences in September 2021. The first event, the H.C. Wainwright Annual Global Investment Conference, is set for September 13-15, where CEO Richard A. Miller will offer a pre-recorded presentation available starting September 13 at 7:00 am ET. The second event, the Cantor Virtual Global Healthcare Conference, runs from September 27-30, with Dr. Miller presenting on September 29 from 3:20-3:50 pm ET. Webcast replays will be accessible for 90 days post-event.

Corvus Pharmaceuticals (Nasdaq: CRVS) announced that its partner, Angel Pharmaceuticals, received approval for a Phase 1/1b clinical trial of CPI-818 in China for T cell lymphomas. This milestone, expected to initiate by year-end 2021, underscores Corvus’ global growth strategy. CPI-818, an ITK inhibitor, shows potential in treating T cell malignancies, with interim trial results demonstrating significant tumor responses. Additionally, Angel Pharma launched new R&D centers in China and the U.S., enhancing its capabilities in drug development.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) reported its Q2 2021 financial results, revealing cash reserves of $66.5 million, up from $44.3 million at year-end 2020. The company continues to develop mupadolimab for HPV+ head and neck cancer and other viral-related cancers, having begun a Phase 1b/2 trial. Corvus discontinued its Phase 3 COVID-19 trial, reducing expected 2021 operating cash use to $35-$37 million, down from $46-$48 million. R&D expenses rose to $9.1 million, resulting in a net loss of $11.8 million for the quarter.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced the discontinuation of its Phase 3 study of mupadolimab for COVID-19, citing successful vaccine trends. The company will focus on oncology, particularly for HPV+ head and neck cancer, where mupadolimab is in an ongoing Phase 1/1b trial. Initial evidence suggests its effectiveness in enhancing immune responses. Additionally, Corvus reduced its projected 2021 net cash used in operating activities by $11 million, now estimating between $35-37 million. The company had $66.5 million in cash as of June 30, 2021.

BURLINGAME, Calif., May 25, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 4:00-4:25 pm ET. The presentation will be available via live webcast and accessible for 30 days afterwards through the investor relations section of Corvus' website.

Corvus focuses on developing innovative therapies, with lead candidate mupadolimab in Phase 3 trials for COVID-19 and ongoing studies for T-cell lymphomas. For detailed information, visit www.corvuspharma.com.

Corvus Pharmaceuticals (NASDAQ:CRVS) announced the completion of a $10 million common share sale through its ATM program, with 3,564,228 shares sold to EcoR1 Capital and 35,714 shares to CEO Richard A. Miller at $2.80 per share. The settlement is set for May 6, 2021. This follows an effective shelf registration statement declared on March 19, 2020. Investors are encouraged to review the related prospectus available on the SEC's EDGAR database or by contacting Jefferies LLC directly. The company is focused on advancing its clinical programs, including CPI-006 and CPI-818.

Corvus Pharmaceuticals (Nasdaq: CRVS) provided a business update and reported Q1 2021 financial results. The company is advancing its Phase 3 trial for CPI-006 in hospitalized COVID-19 patients, with full enrollment expected by year-end. Financially, Corvus reported cash and equivalents of $68 million, up from $44.3 million in Q4 2020, aided by a $32 million equity offering. R&D expenses decreased to $8.2 million, while the net loss narrowed to $11.6 million. Corvus is also progressing with CPI-818 and ciforadenant clinical trials, showcasing potential in cancer treatments.

Corvus Pharmaceuticals (CRVS) reported a business update and financial results for Q4 and the full year of 2020. They initiated a Phase 3 study for CPI-006 targeting COVID-19, which showed promising Phase 1 results with no patients requiring mechanical ventilation. Additionally, Corvus co-founded Angel Pharmaceuticals to expedite drug development in China. Financially, they ended 2020 with $44.3 million in cash, down from $78.0 million in 2019 and projected a cash burn of $46-$48 million for 2021. The company reported a net income of $27.1 million for Q4 2020.